195615-83-9

195615-83-9 structure

Name: Blarcamesine
Chemical Name: 1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine
CAS Number: 195615-83-9
Molecular Formula: C₁₉H₂₃NO
Molecular Weight: 281.39200
Catalog: Signaling Pathways GPCR/G Protein mAChR
Create Date: 2017-05-04 02:11:19
Modify Date: 2024-01-11 18:08:14
Blarcamesine (AVex-73;AE-37) is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome[1].

Name	1-(2,2-diphenyloxolan-3-yl)-N,N-dimethylmethanamine
Synonyms	UNII-9T210MMZ3F 3-Furanmethanamine,tetrahydro-N,N-dimethyl-2,2-diphenyl Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanemethanamine AE37 THD-DP-FM

Description	Blarcamesine (AVex-73;AE-37) is an orally bioavailable Sigma-1 receptor agonist and muscarinic receptor modulator, with anticonvulsant, anti-amnesic, neuroprotective and antidepressant properties. Blarcamesine ameliorates neurologic impairments in a mouse model of Rett syndrome[1].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> mAChR Signaling Pathways >> GPCR/G Protein >> mAChR Signaling Pathways >> GPCR/G Protein >> Sigma Receptor
Target	Sigma-1 receptor, muscarinic receptor[1]
In Vivo	Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration[1]. Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice[1]. Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response[1]. Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice[1]. Animal Model: Female Mecp2tm1.1Bird/J HET (C57 background) mice[1] Dosage: 10 mg/kg, 30 mg/kg Administration: Oral administration, daily, for 6.5 weeks Result: Reverse the deficits observed in the HET animals.
References	[1]. Walter E Kaufmann, et al. ANAVEX®2-73 (Blarcamesine), a Sigma-1 Receptor Agonist, Ameliorates Neurologic Impairments in a Mouse Model of Rett Syndrome. Pharmacol Biochem Behav . 2019 Dec;187:172796.